Keyphrases
Acute Myeloid Leukemia
87%
Leukemogenesis
33%
Decitabine
33%
Overall Survival
19%
Infection Management
16%
Overall Response Rate
16%
Ionizing Radiation
16%
Therapeutic Goals
16%
Secondary Type
16%
Infection Prevention
16%
Relapsed or Refractory Acute Myeloid Leukemia
16%
Clonal Evolution
16%
Newly Diagnosed
16%
FMS-like Tyrosine Kinase 3 (FLT3)
16%
Treatment Regimen
16%
Infectious Complications
11%
Low Intensity
10%
Intensive Chemotherapy
10%
Chromatin Remodeling
8%
Molecular Cytogenetics
8%
Treatment Strategy
8%
Molecular Mechanism
8%
Novel Therapeutics
8%
Treatment-related
8%
Cellular Pathways
8%
Dysplasia
8%
Targeted Therapy
8%
Splicing Factor
8%
Mechanism Pathway
8%
Molecular Landscape
8%
Combination Strategy
8%
Myelodysplastic Neoplasms
8%
Molecular Treatment
8%
Therapeutic Combinations
8%
Cohesin Complex
8%
European LeukemiaNet
8%
Aberrancy
8%
Myeloid Maturation
8%
Rational Therapeutics
8%
FLT3 Inhibitor
7%
Aberrations
7%
Clinical Impact
7%
Treatment Combination
7%
Relapsed or Refractory
6%
Median Overall Survival
6%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
6%
Solid Organ
5%
Transcription Factor
5%
Clonal Proliferation
5%
Cell Cycling
5%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Decitabine
50%
Overall Survival
21%
Venetoclax
19%
Ionizing Radiation
16%
Infection
16%
Leukemogenesis
16%
Azacitidine
16%
Diseases
16%
FMS-Like Tyrosine Kinase 3
16%
Retrospective Study
16%
Prognostication
15%
Infectious Complication
11%
Chromatin Remodeling
8%
Acute Myelogenous Leukemia
8%
Cohesin
8%
Maturation
8%
Targeted Therapy
8%
Dysplasia
8%
Neoplasm
8%
Pharmacokinetic
8%
Hypomethylating Agent
6%
Allogeneic Stem Cell Transplantation
6%
Mycosis
5%
Bone Marrow Toxicity
5%
Organ Systems
5%
Virus Infection
5%
Antiinfective Agent
5%
Disease Predisposition
5%
Leukopenia
5%
Bacterial Infection
5%
Cell Transduction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
83%
Decitabine
50%
Leukemogenesis
33%
Azacitidine
16%
Infection
16%
Ionizing Radiation
16%
Venetoclax
16%
Overall Survival
16%
Neoplasm
13%
Infectious Complication
11%
Dysplasia
8%
Cohesin
8%
Pharmacokinetic
8%
Virus Infection
5%
Disease Predisposition
5%
Leukopenia
5%
Bacterial Infection
5%
Bone Marrow Toxicity
5%
Transcription Factor
5%
Mycosis
5%
Antiinfective Agent
5%
